# A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

> **NCT06764940** · PHASE2 · RECRUITING · sponsor: **Biostar Pharma, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- HER2-negative Breast Cancer Patients With Brain Metastases

## Interventions

- **DRUG:** Utidelone
- **DRUG:** Utidelone in combination with capecitabine
- **DRUG:** Utidelone in combination with capecitabine
- **DRUG:** Utidelone in combination with capecitabine

## Key facts

- **NCT ID:** NCT06764940
- **Lead sponsor:** Biostar Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-07-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764940, "A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06764940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*